Luveltamab tazevibulin,Pegfilgrastim
Sutro Biopharma,Amgen
['pivotal study', 'pivot,io,i', 'ovarian', '$stro', 'sutro']
$stro sutro biopharma announces oral presentation at asco 2023 featuring data for luveltamab tazevibulin from the phase 1 dose-expansion study in ovarian cancer and the initiation of the phase 2/3 pivotal study refra #cancer #clinicaltrial 
Stay ahead of the market with ultra-fast stock news updates. 
FREE with 15 sec delay. Upgrade to Gold for even faster news & exclusive features @ https://t.co/LViEqnfZ7i